Reply to Sfeir

Affiliations

Comment

Johann Motsch et al. Clin Infect Dis. 2021.

. 2021 Apr 26;72(8):1485-1486.

doi: 10.1093/cid/ciaa881.

No abstract available

Comment on

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng HK, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A. Motsch J, et al. Clin Infect Dis. 2020 Apr 15;70(9):1799-1808. doi: 10.1093/cid/ciz530. Clin Infect Dis. 2020. PMID: 31400759 Free PMC article. Clinical Trial.
Imipenem-relebactam for Treatment of Carbapenem-resistant Gram-negative Bacteria: Where Do We Stand on In Vitro Susceptibility Testing?
Sfeir MM. Sfeir MM. Clin Infect Dis. 2021 Apr 26;72(8):1484-1485. doi: 10.1093/cid/ciaa878. Clin Infect Dis. 2021. PMID: 32634243 No abstract available.